Business Context and Reporting Period
Company: Oncolytics Biotech Inc. (ONCY)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Oncolytics is a clinical-stage biopharmaceutical company developing pelareorep, an oncolytic virus immunotherapeutic agent. The company has no approved products for commercial sale and has not generated operating revenue. Its primary focus is advancing clinical programs for hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma (PDAC).
Accounting Basis: International Financial Reporting Standards (IFRS). All figures are in Canadian dollars (CAD) unless otherwise noted.
Key Financial Metrics
| Metric (in thousands CAD) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(31,710) | $(27,752) | $(24,835) |
| Research & Development Expenses | $21,647 | $17,709 | $15,432 |
| General & Administrative Expenses | $13,335 | $16,082 | $11,492 |
| Cash and Cash Equivalents (Year End) | $15,942 | $34,912 | $11,666 |
| Accumulated Deficit | $(477,713) | $(446,003) | $(418,251) |
| Total Assets | $20,187 | $38,820 | $36,099 |
| Total Liabilities | $14,204 | $11,257 | $N/A |
| Outstanding Shares | 80,020,131 | 74,423,960 | 61,327,914 |
Liquidity & Debt: The company has no long-term debt. Current liabilities include accounts payable, accrued liabilities, and lease liabilities. A contract liability of $6.73 million exists related to an upfront license fee from Adlai Nortye Biopharma Co., Ltd., which is recognized over time.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by approximately 14% to $31.7 million in 2024 compared to $27.8 million in 2023, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses rose 22% to $21.6 million, reflecting increased clinical trial and manufacturing costs for the pelareorep program.
- Cash Burn: Cash and cash equivalents decreased by 54% from $34.9 million in 2023 to $15.9 million in 2024. Cash used in operating activities was $27.0 million.
- Financing Activity: The company raised $6.9 million through its "At the Market" (ATM) equity distribution agreement in 2024, compared to $10.3 million in 2023. No public offerings occurred in 2024.
- Warrant Derivative: The warrant derivative liability reversed to an asset position of $0.98 million in 2024 (liability of $0.2 million in 2023) due to changes in fair value and unamortized discount.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, the company estimates it has sufficient cash to fund operations only into the third quarter of 2025. Continued operations are dependent on raising additional financing through equity or strategic collaborations.
Clinical Development Outlook
- Breast Cancer: Final results from the BRACELET-1 study showed a median overall survival (OS) benefit for pelareorep plus paclitaxel compared to paclitaxel alone (estimated 32.1 months vs. 18.2 months). The company plans a registration-enabling study.
- Pancreatic Cancer: The GOBLET platform study showed an objective response rate (ORR) of 62% in first-line PDAC patients. A new cohort (GOBLET Cohort 5) utilizing mFOLFIRINOX commenced enrollment in 2024.
Material Risks
- Nasdaq Delisting Risk: On February 13, 2025, the company received a notice from Nasdaq that its share price had been below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until August 12, 2025, to regain compliance.
- Regulatory & Clinical Risks: Failure or delays in clinical trials, inability to secure regulatory approval, or adverse side effects could halt development.
- Partnership Dependency: The company relies on a licensing agreement with Adlai Nortye Biopharma for rights in China and other Asian territories. Geopolitical tensions and trade restrictions pose risks to this agreement.
- PFIC Status: The company is likely a Passive Foreign Investment Company (PFIC), which may have adverse U.S. federal income tax consequences for U.S. shareholders.
Unusual Items
The company received a grant from the Pancreatic Cancer Action Network (PanCAN) to fund a Phase 1/2 study. Unapplied funding of $1.6 million is recorded as a liability. Subsequent to year-end (Jan-Mar 2025), the company raised an additional $6.0 million in net proceeds via its ATM agreement.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round given the Q3 2025 cash runway estimate.
- Nasdaq Compliance: Monitor the share price to determine if the company will meet the $1.00 bid price requirement by August 12, 2025, to avoid delisting.
- Clinical Milestones: Track enrollment and data readouts for the planned registration-enabling breast cancer trial and the GOBLET pancreatic cancer cohorts.
- Partnership Status: Assess the stability of the Adlai Nortye Biopharma agreement amidst U.S.-China trade tensions.
- Dilution Risk: Review the terms of the Base Shelf prospectus and ATM agreement to understand potential dilution from future equity issuances.